These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 20859122)

  • 1. Thymic tumors: relevant molecular data in the clinic.
    Girard N
    J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutational status of EGFR and KIT in thymoma and thymic carcinoma.
    Yoh K; Nishiwaki Y; Ishii G; Goto K; Kubota K; Ohmatsu H; Niho S; Nagai K; Saijo N
    Lung Cancer; 2008 Dec; 62(3):316-20. PubMed ID: 18448188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy-relevant mutations of receptor tyrosine kinases in malignant thymomas and thymic carcinomas: a therapeutic perspective].
    Ströbel P; Knop S; Einsele H; Müller-Hermelink HK; Marx A
    Verh Dtsch Ges Pathol; 2007; 91():177-86. PubMed ID: 18314613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absence of gene mutations in KIT-positive thymic epithelial tumors.
    Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
    Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic treatment of advanced thymic malignancies.
    Kelly RJ
    Am Soc Clin Oncol Educ Book; 2014; ():e367-73. PubMed ID: 24857125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
    Girard N; Shen R; Guo T; Zakowski MF; Heguy A; Riely GJ; Huang J; Lau C; Lash AE; Ladanyi M; Viale A; Antonescu CR; Travis WD; Rusch VW; Kris MG; Pao W
    Clin Cancer Res; 2009 Nov; 15(22):6790-9. PubMed ID: 19861435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors.
    Suzuki E; Sasaki H; Kawano O; Endo K; Haneda H; Yukiue H; Kobayashi Y; Yano M; Fujii Y
    Jpn J Clin Oncol; 2006 Jun; 36(6):351-6. PubMed ID: 16762968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and mutational status of c-kit in thymic epithelial tumors.
    Petrini I; Zucali PA; Lee HS; Pineda MA; Meltzer PS; Walter-Rodriguez B; Roncalli M; Santoro A; Wang Y; Giaccone G
    J Thorac Oncol; 2010 Sep; 5(9):1447-53. PubMed ID: 20651610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas.
    Meister M; Schirmacher P; Dienemann H; Mechtersheimer G; Schnabel PA; Kern MA; Herpel E; Xu EC; Muley T; Thomas M; Rieker RJ
    Cancer Lett; 2007 Apr; 248(2):186-91. PubMed ID: 16919868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy and targeted agents for thymic malignancies.
    Girard N
    Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor expression in invasive thymoma.
    Henley JD; Koukoulis GK; Loehrer PJ
    J Cancer Res Clin Oncol; 2002 Mar; 128(3):167-70. PubMed ID: 11935304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-1 receptor expression in thymic malignancies.
    Girard N; Teruya-Feldstein J; Payabyab EC; Riely GJ; Rusch VW; Kris MG; Zakowski MF
    J Thorac Oncol; 2010 Sep; 5(9):1439-46. PubMed ID: 20736806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase receptor expression in thymomas.
    Henley JD; Cummings OW; Loehrer PJ
    J Cancer Res Clin Oncol; 2004 Apr; 130(4):222-4. PubMed ID: 14762710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies for thymic malignancies.
    Girard N
    Thorac Surg Clin; 2011 Feb; 21(1):115-23, viii. PubMed ID: 21070993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).
    Tiseo M; Damato A; Longo L; Barbieri F; Bertolini F; Stefani A; Migaldi M; Gnetti L; Camisa R; Bordi P; Buti S; Rossi G
    Lung Cancer; 2017 Feb; 104():24-30. PubMed ID: 28212996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
    Pagano M; Sierra NM; Panebianco M; Rossi G; Gnoni R; Bisagni G; Boni C
    Anticancer Res; 2014 Sep; 34(9):5105-10. PubMed ID: 25202099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aberrant methylation: common in thymic carcinomas, rare in thymomas.
    Suzuki M; Chen H; Shigematsu H; Ando S; Iida T; Nakajima T; Fujisawa T; Kimura H
    Oncol Rep; 2005 Dec; 14(6):1621-4. PubMed ID: 16273266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib.
    Ströbel P; Hartmann M; Jakob A; Mikesch K; Brink I; Dirnhofer S; Marx A
    N Engl J Med; 2004 Jun; 350(25):2625-6. PubMed ID: 15201427
    [No Abstract]   [Full Text] [Related]  

  • 19. Impressive response with imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma.
    Buti S; Donini M; Sergio P; Garagnani L; Schirosi L; Passalacqua R; Rossi G
    J Clin Oncol; 2011 Nov; 29(33):e803-5. PubMed ID: 21969494
    [No Abstract]   [Full Text] [Related]  

  • 20. COX-2 upregulation in thymomas and thymic carcinomas.
    Rieker RJ; Joos S; Mechtersheimer G; Blaeker H; Schnabel PA; Morresi-Hauf A; Hecker E; Thomas M; Dienemann H; Schirmacher P; Kern MA
    Int J Cancer; 2006 Nov; 119(9):2063-70. PubMed ID: 16823844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.